Dr. David Fortin and his team are dedicated to research in neuro-oncology, aiming to extend the life expectancy and quality of life of patients with aggressive brain tumors. Their work focuses on manipulating the blood-brain barrier to optimize the delivery of anticancer drugs and on developing cellular models of gliomas. A major breakthrough in the laboratory is a revolutionary chemotherapy technique that temporarily opens the blood-brain barrier, allowing drugs to reach the tumor effectively.
This approach has already enabled some patients to live on average three times longer than with traditional treatments.
The laboratory is also developing a liposomal platform to enhance this targeted therapy.
Current research projects include:
- Personalized selection of intra-arterial chemotherapy for glioblastoma multiforme.
- Studies on prognostic biomarkers and their clinical correlation.
- Development of new therapeutic modalities, such as intra-arterial chloroquine or intra-tumoral carboplatin infusion.
- Clinical trials combining chemotherapy and radiotherapy.
- Analysis of the impact of intra-arterial chemotherapy on survival of patients treated at CHUS since 2000.
- Creation of real-time interactive brain imaging tools to improve surgical planning.
Every year, approximately 2,500 Canadians are diagnosed with brain cancer. This disease remains one of the most aggressive and difficult to treat. Dr. Fortin and his team’s work provides tangible advancements and promising perspectives for those affected by this disease, by developing innovative therapies and targeted techniques to improve patient survival and quality of life. Thanks to this research, new therapeutic options are emerging, bringing hope and support to patients and their families.
© 2024 AIMapps Inc